Liver Metastases Studies

Principle Investigator:

Gregory A. Wiseman, M.D.
Email: gwiseman@mayo.edu
Secretary phone: 507–284–4399

Study Coordinator:
Teresa Mettler, RN
Email: mettler.teresa@mayo.edu
Phone: 507–538–0015

An Open Label Trial of TheraSphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine or Non-Colorectal/Non-Neuroendocrine Cancer

Specific Aims:

Primary:

• To evaluate Progression Free Survival (PFS) following TheraSphere treatment, as determined by CT/MRI images according to RECIST criteria.
• To evaluate the safety of TheraSphere treatment at doses of 120 ± 10% Gy in patients with metastatic disease to the liver.